<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049967</url>
  </required_header>
  <id_info>
    <org_study_id>ILMN-iKnow</org_study_id>
    <nct_id>NCT05049967</nct_id>
  </id_info>
  <brief_title>iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders</brief_title>
  <acronym>iKnow</acronym>
  <official_title>iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illumina, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Illumina, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational study to further understand the value that a multi-omic approach&#xD;
      has in individuals with a multi system, early onset disorder that does not have a molecular&#xD;
      diagnosis by whole genome sequencing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Understand the value and utilization of integrated multi-omics, in multi-system early onset&#xD;
      disorders that have failed to yield findings by whole genome sequencing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Based on analysis of data from completed clinical utility evaluation surveys following receipt of study results by the PI, assess whether a patient's change of management resulted from the multi-omic results</measure>
    <time_frame>120 Days</time_frame>
    <description>Understand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of diagnoses yielded by each of the different orthogonally confirmed assay results</measure>
    <time_frame>120 Days</time_frame>
    <description>Assess the number of new diagnoses yielded by each approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze data from completed clinical utility evaluation surveys; number of patients with change of management and whether the change was due to a diagnosis yielded by multiomic results</measure>
    <time_frame>120 Days</time_frame>
    <description>Analyze the clinical utility derived from a diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data utilization of multi-omic dataset for scientific community</measure>
    <time_frame>120 Days</time_frame>
    <description>Establish a multi-omic reference dataset from resource limited populations that can be used by the scientific community</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Genetic Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Outpatient setting with eighty percent consisting of prior negative genome cases that have&#xD;
      previously received a clinical whole genome sequencing (cWGS) test. Remaining twenty percent&#xD;
      will be positive controls who previously have a definitive diagnosis from clinical genetic&#xD;
      testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient setting with eighty percent consisting of prior negative genome cases that have&#xD;
        previously received a clinical whole genome sequencing (cWGS) test. Remaining twenty&#xD;
        percent will be positive controls who previously have a definitive diagnosis from clinical&#xD;
        genetic testing.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undiagnosed probands must meet all of the following:&#xD;
&#xD;
               1. Must be able to understand and sign an informed consent and speak, read, and&#xD;
                  write in their native language (if the subject is a minor, their parent must have&#xD;
                  these abilities)&#xD;
&#xD;
               2. Proband between the ages of 12 months and 65 years&#xD;
&#xD;
               3. Study consent and participation of at least two unaffected family members&#xD;
                  (biological parents preferred. One biological parent and unaffected sibling&#xD;
                  allowed)&#xD;
&#xD;
               4. If applicable, unaffected sibling must be between the ages of 12 months and 65&#xD;
                  years&#xD;
&#xD;
               5. A high prior probability of a multi-system early onset undiagnosed genetic&#xD;
                  disorder based on an expert medical assessment&#xD;
&#xD;
               6. Clinical WGS that did not yield a definitive diagnosis&#xD;
&#xD;
               7. It is preferred but not required that ancestry is from an under-represented&#xD;
                  population in current clinical genetic and translational research data&#xD;
                  repositories, especially African American, Asian American and Native American&#xD;
&#xD;
               8. Must be willing to have blood, urine and fecal samples taken to include&#xD;
                  participating family members&#xD;
&#xD;
        Diagnosed probands must meet all of the following:&#xD;
&#xD;
          1. Must be able to understand and sign an informed consent and speak, read, and write in&#xD;
             their native language (if the subject is a minor, its Parent or Legally Authorized&#xD;
             Representative must have these abilities).&#xD;
&#xD;
          2. Proband between the ages of 12 months and 65 years&#xD;
&#xD;
          3. Study consent and participation of at least two unaffected family members (biological&#xD;
             parents preferred. One biological parent and unaffected sibling allowed)&#xD;
&#xD;
          4. If applicable, unaffected sibling must be between the ages of 12 months and 65 years&#xD;
&#xD;
          5. Known genetic cause(s) of disease, disorder, or phenotypic defect through prior&#xD;
             clinical whole genome sequencing&#xD;
&#xD;
          6. It is preferred but not required that ancestry is from an under-represented population&#xD;
             in current clinical genetic and translational research data repositories, especially&#xD;
             African American, Asian American and Native American&#xD;
&#xD;
          7. Must be willing to have blood, urine and fecal samples taken to include participating&#xD;
             family members&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undiagnosed probands must not meet any:&#xD;
&#xD;
               1. Known non-genetic cause(s) of disease, disorder, or phenotypic defect&#xD;
&#xD;
               2. Principal Investigator decides that the study is not in the best interest of the&#xD;
                  proband&#xD;
&#xD;
        Diagnosed probands must not meet any:&#xD;
&#xD;
        1. Principal Investigator decides that the study is not in the best interest of the proband&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan J Taft, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Illumina, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Pierce</last_name>
    <phone>8585393970</phone>
    <email>jpierce1@illumina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Cung</last_name>
    <phone>8585393970</phone>
    <email>kcung@illumina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic for Special Children</name>
      <address>
        <city>Strasburg</city>
        <state>Pennsylvania</state>
        <zip>17579</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlla Brigatti</last_name>
      <phone>717-687-9407</phone>
      <email>kbrigatti@clinicforspecialchildren.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

